Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects

NCT04775706 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Short Bowel Syndrome

Interventions

DRUG: HM15912 Active
DRUG: Placebo

Sponsor

Hanmi Pharmaceutical Company Limited